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Abstract
Background: Adenomyoepithelial tumours and myoepithelial carcinomas of the breast are primarily
defined by the presence of neoplastic cells with a myoepithelial immunophenotype. Current classification
schemes are based on purely descriptive features and an assessment of individual prognosis is still
problematic.
Methods: A series of 27 adenomyoepithelial tumours of the breast was analysed immunohistochemically
with antibodies directed against various cytokeratins, p63, smooth muscle alpha-actin (SMA) and vimentin.
Additionally, double immunofluorescence and comparative genomic hybridisation (CGH) was performed.
Results: Immunohistochemically, all the tumours showed a constant expression of high molecular weight
cytokeratins (Ck) Ck5 and Ck14, p63, SMA and vimentin. With exception of one case diagnosed as
myoepithelial carcinoma, all tested tumours expressed low molecular weight cytokeratin Ck18 in variable
proportions of cells. Even in monophasic tumours lacking obvious glandular differentiation in conventional
staining, a number of neoplastic cells still expressed those cytokeratins. Double immunofluorescence
revealed tumour cells exclusively staining for Ck5/Ck14 in the presence of other cell populations that co-
expressed high molecular weight Ck5/Ck14 as well as either low molecular weight Ck8/18 or SMA. Based
on morphology, we assigned the series to three categories, benign, borderline and malignant. This
classification was supported by a stepwise increase in cytogenetic alterations on CGH.
Conclusion: Adenomyoepithelial tumours comprise a spectrum of neoplasms consisting of an admixture
of glandular and myoepithelial differentiation patterns. As a key component SMA-positive cells co-
expressing cytokeratins could be identified. Although categorisation of adenomyoepithelial tumours in
benign, borderline and malignant was supported by results of CGH, any assessment of prognosis requires
to be firmly based on morphological grounds. At present it is not yet clear, if and to what extent proposed
Ck5-positive progenitor cells contribute to the immunohistochemical and morphological heterogeneity of
these neoplasms of the breast.
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Background
Adenomyoepithelial tumours are a widely accepted, yet
poorly understood diagnostic entity of breast neoplasms,
the definition of which is based on cytological and archi-
tectural features. According to the most recent WHO clas-
sification, the spectrum of tumours included under this
heading ranges from organoid, bi-phasic tumors with a
combination of easily recognisable tubular formations
and multi-layered spindle-celled myoepithelial elements
to monophasic lesions with "mesenchymal" appearance
[1-3].
In tumours of monophasic "mesenchymal" appearance, a
potentially glandular differentiation can sometimes only
be identified by staining for low-molecular-weight cytok-
eratins (Ck) Ck8/18. Malignant tumours without obvious
morphological and immunophenotypic glandular fea-
tures are currently classified as malignant myoepitheli-
oma or myoepithelial carcinoma. These malignancies are
characterized by infiltrating proliferations of atypical
spindle cells with high mitotic activity, often displaying a
dot-like cytoplasmic expression of smooth muscle α-actin
(SMA), vimentin and Ck14. Because of this phenotypic
heterogeneity, a specific position within the spectrum of
proliferative breast lesions has not been assigned to aden-
omyoepithelial neoplasms, and unequivocal criteria for
prognostic assessment have not yet been established [4,5].
We studied a series of 27 adenomyoepithelial tumours by
comparative genomic hybridisation (CGH), double
immunofluorescence and immunostaining for Ck5,
Ck14, Ck8/18 and Ck19, as well as for vimentin, p63,
SMA and the proliferation antigen detected by the mono-
clonal antibody MIB-1. Our data indicates that adenom-
yoepithelial tumours represent a spectrum of lesions that




Tissue blocks of 27 cases, most of them referral cases, were
selected from the files of the Institutes of Pathology of
Muenster University Hospital and Kantonsspital St. Gal-
len. The tissue material had been fixed in neutral buffered
formalin and paraffin-embedded according to standard
procedures. Diagnoses were based on morphologic crite-
ria using haematoxylin and eosin (H&E)-stained sections
and immunohistology for Ck5 and Ck14, Ck8/18 and sm-
actin. The clinical data, as far as available, is summarised
in Table 1. The median age of patients presenting with a
benign adenomyoepithelial tumour was 51 years, all
patients were female. The median age of the patients with
malignant adenomyoepithelial tumours was 53 years.
Tumours classified as benign comprised a broad spectrum
of histological differentiation ranging from biphasic
lesions with well definable tubular structures to
monophasic types, whereas almost all malignant tumours
displayed a "mesenchymal" appearance. In order to be
classified as benign, adenomyoepithelial tumours had to
fulfil the following criteria: benign cytomorphology, a
mitotic rate of less than 15 %, and absence of invasive fea-
tures. Malignancy was diagnosed when the following cri-
teria were met: a mitotic rate exceeding 15 % and/or
malignant cytomorphology and/or invasive growth pat-
tern. Those cases that did not fit either group were
regarded as borderline tumours.
Immunohistology
Paraffin sections of 8 benign, 5 borderline-type and 14
malignant adenomyoepithelial tumours were stained
with antibodies (Table 2) using LSAB/ HRP (Ventana
Nexes, Ventana Medical Systems, Tuscon, USA) or the
LSAB/ AP (DAKO-Autostainer, DAKO Hamburg, Ger-
many) techniques with DAB or Red as substrates,
respectively.
Double immunofluorescence experiments
After incubation with a first primary monoclonal anti-
body (mAb) sections were washed and incubated with
FITC-conjugated rabbit anti-mouse antibodies (Dianova,
Hamburg, Germany; diluted 1 : 50). They were then incu-
bated with the second primary mAb that had been bioti-
nylated previously (ARK™ biotinylating kit; Dako). The
biotin label was subsequently visualised with Cy3-conju-
gated streptavidin (Dianova, 1 : 200). SMA was detected
using a directly FITC-conjugated antibody. Counterstain-
ing was performed with DAPI (Sigma, 5 µg/ml Tris buffer)
for 15 s, and specimens were mounted with Vectashield
(Vector Laboratories, Burlingame, USA). Controls were
incubated without primary antibody or with mouse IgG.
All cases were also stained using conventional enzyme
immunolabeling [6].
Microscopy and image processing
Immunostained slides were examined using a Zeiss Axio-
plan 2 bright field/fluorescence microscope equipped
with appropriate filters. Separate images for DAPI, Cy3,
and FITC staining were captured digitally from double-
stained specimens into colour-separated components
using an AxioCam digital camera (Carl Zeiss, Göttingen,
Germany) and AxioVision 2.05 multi-channel image
processing (Carl Zeiss Vision GmbH, Hallbergmoos, Ger-
many). The red (for Cy3), blue (for DAPI), and green (for
FITC) components were merged and composed for fur-
ther analysis.
Microdissection and DNA extraction
Manual microdissection was performed with a minimum
of ten serial sections of 10 µm thickness cut from the par-
affin blocks of all of the benign and malignantBMC Cancer 2005, 5:92 http://www.biomedcentral.com/1471-2407/5/92
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adenomyepithelial tumour specimens. DNA extraction
was performed according to standard protocols of protei-
nase K digestion (1 mg/ml) followed by phenol-chloro-
form extraction.
Comparative genomic hybridisation (CGH)
As previously described [7,8] fluorescence labeling of 900
ng DNA extracted from microdissected tissue was carried
out by standard nick-translation reactions with biotin-16-
deoxy-uridine-triphosphate (dUTP; Boehringer Man-
nheim, Mannheim, Germany). 300 ng of reference DNA
from a healthy female donor was labeled with digoxi-
genin-11-dUTP (Boehringer Mannheim).
Regional shifts of the fluorescence ratio profile exceeding
the 1.5 threshold were rated as amplifications. Since the
target metaphase slides occasionally showed false-positive
signals at 1p32-pter, 16p and the entire chromosome 19,
those regions were excluded from our analysis.
Results
Conventional histology
The adenomyoepithelial tumours analysed in this series
displayed great morphological heterogeneity with varia-
ble growth patterns and cytological differentiations. All
tumours showed at least foci of hyalinisation, sometimes
in a basement membrane-like pattern with narrow eosin-
red bands enmeshing the tumour cells, sometimes with
prominent hyalinisation. Eight tumours were diagnosed
as benign adenomyoepithelial tumours (Fig. 1, A, B)
because they were architecturally inconspicuous and
showed neither cytological atypia nor invasive growth.
Table 1: Clinical data and results of conventional histology and immunohistology of adenomyoepithelial tumours of the breast.
Case age Diagnosis Pleomorphism Necrosis Tumour 
border
CK14 Ck19 Ck18 CD117 Vim P63 Ck5/6 S100 KL-1 SMA MIB-
1[%]
ER PR Mitoses/ 
10HPF
1 42 benign, biphasic AM/ tubular 0 0 s (+++) (++) (++) (++) (+) (+++) (+++) nd (+) (+++) 2 (+) (+) 0
2 57 benign, biphasic AM/ 
tubular/ spindle-cellular
(+) 0 s (+++) (+++) (+++) 0 (+) nd (+++) nd (+++) (+++) 5 (+++) (++) 0
3 50 benign, biphasic AM/ 
tubular/ lobular
(+) (+) s (++) (0) (+) (++) (++) (+++) (+++) nd (+) (+) 10 0 0 1
4 75 benign, biphasic AM/ lobular (+) 0 s (+) (++) (++) (+) (+) (+++) (++) nd (+) (++) 10 (+) 0 0
5 80 Benign, biphasic AM/ lobular (+) (+) i (++) (+) (+) (++) nd (+++) (++) (+) (+) (++) 10 0 0 0
6 59 benign, biphasic AM/ 
tubular/ spindle-cellular
(+) 0 s nd nd nd nd (+) nd (+++) nd (++) (+++) 15 (+++) 0 1
7 65 benign, monophasic AM/ 
spindle-cellular
(+) 0 s (+++) 0 (+++) 0 (+++) nd (+++) (+++) (+++) (+++) 1 0 0 0
8 80 benign, biphasic AM/ 
tubular/ spindle-cellular
(+) 0 s (+++) (+++) (+++) (+) (+) nd (++) (++) (++) (++) 5 0 0 2
9 64 borderline, monophasic AM/ 
spindle-cellular
(+) 0 i (+++) 0 (+) (+) (+++) (+++) (+++) nd (+) (+++) 20 0 0 1
10 78 borderline, monophasic AM/ 
spindle-cellular
(++) (+) i nd nd nd nd nd (+) (+++) (+) (+) (+) 30 0 0 1
11 84 borderline, monophasic AM/ 
spindle-cellular
(+++) 0 i (+++) 0 (+) (+) (+++) nd (+++) nd (+) (++) 10 0 0 1
12 95 borderline, monophasic AM/ 
spindle-cellular
(++) 0 i nd nd nd nd nd nd (+++) (+) (+) (+) 20 0 0 1
13 66 borderline, monophasic AM/ 
spindle-cellular
(+++) (+) i (+++) 0 (+) (++) (+++) (+++) (+) nd 0 (+) 10 0 0 0
14 71 malignant, monophasic AM/ 
spindle-cellular
(+++) (+) i (+++) 0 (+) (+) (+++) (+++) (++) nd (+) (+) 20 0 0 1
15 68 malignant, monophasic AM/ 
spindle-cellular
(++) (+) i (+++) (++) (+) (+) (+++) (+++) (+++) (+) (+) (++) 40 0 0 12
16 93 malignant Myoepithelioma (+++) (+) i (+) 0 0 (++) (+++) (+++) (+++) nd (+) (++) 40 0 0 8
17 85 malignant, monophasic AM/ 
spindle-cellular
(+++) (+) i (+++) 0 (+) (+) (+++) (+++) (+++) nd (+) (++) 20 0 0 1
18 48 malignant, monophasic AM/ 
spindle-cellular
(++) 0 i nd nd nd nd nd nd (+++) nd (+) (+++) 25 0 0 6
19 ? malignant, monophasic AM/ 
spindle-cellular
(+++) (+) i (+++) (+) (+) 0 (++) (+++) (+) (+) (+) (+) 50 0 0 25
20 81 malignant, monophasic AM/ 
spindle-cellular
(+++) (+) i nd nd nd nd nd nd (+++) (+) (+) (+) 20 0 0 2
21 87 malignant, monophasic AM/ 
spindle-cellular
(+++) (+) i (+++) 0 (+) 0 (+++) nd (+++) 0 (++) (+++) 50 0 0 10
22 55 malignant, monophasic AM/ 
spindle-cellular
(+++) (+) i (+++) (+++) (++) (+) (+++) nd (+++) (+) (+) (+) 80 0 0 22
23 60 malignant, biphasic AM/ 
spindle-cellular
(+++) (+++) i (+++) (+) (+++) (++) (+++) nd (+++) (+++) (+++) (+++) 30 0 0 2
24 82 malignant, monophasic AM/ 
spindle-cellular
(+++) (+++) i (+++) (++) (++) (++) 0 nd (+) (+) (+) (+++) 75 0 0 12
25 57 malignant, monophasic AM/ 
spindle-cellular
(++) (++) i (+++) (+) (+) (+) (+) nd (++) (+) (+) (++) 70 0 0 62
26 45 malignant, monophasic AM/ 
spindle-cellular
(+++) (+++) i (+) (+++) (++) (++) (++) nd (++) (+++) (+) (++) 30 0 0 7
27 45 malignant, monophasic AM/ 
spindle-cellular
(++) (+++) i (+) (+++) (+++) (++) (++) nd (+) (+) (+++) (++) 60 0 0 11
S = sharply bordered lesions, i = infiltrative growth patternBMC Cancer 2005, 5:92 http://www.biomedcentral.com/1471-2407/5/92
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Five of these were biphasic with a combination of tubular
structures and multilayered myoepithelial elements,
whereas three showed additional areas of pure spindle-
cell differentiation with bland cytomorphology. In only
one of these a "lobular" growth pattern was found.
Another two cases were characterized by a lobular growth
pattern and one case by pure spindle cell differentiation.
The growth fraction (MIB-1 labeling index) did not exceed
15 %.
Fourteen adenomyoepithelial tumours were diagnosed as
malignant (Fig. 2 A, B) in view of their cytological aspect,
an infiltrative or destructive growth pattern and necrosis.
The growth fraction exceeded 15 % in all those cases.
These malignant adenomyoepithelial tumours often dis-
played a monophasic pattern consisting of spindle-
shaped "mesenchymal" cells only. The cells were fre-
quently arranged in a reticular, somewhat more cohesive
pattern reminiscent of an abortive glandular differentia-
tion. Other tumours showed an interwoven, storiform
pattern and some displayed solid areas with an epitheloid
or plasmacytoid aspect. Only one of these malignant
tumours contained well-developed tubular structures and
was diagnosed as biphasic malignant adenomyoepithelial
tumour.
Five lesions could not be included in either of the above
groups because they only showed some, but not all the
malignant features. Diagnosed as borderline tumours,
they displayed a conspicuous cytological variety with a
growth fraction ranging from 10 to 30 % and, in some
cases, focal necrosis. Irregularities in margin composition
were not diagnosed as infiltrative growth. All the tumours
of this group were predominantly of spindle-cell type. In
six cases (22 %) of diverse prognostic groups metaplastic
squamous cells were found to grow in small nests of kerat-
inizing cells. Only one of the twenty-seven tumours which
completely lacked glandular differentiation as well as Ck
8/18 expression was classified as pure myoepithelial
carcinoma.
Double immunofluorescence experiments with two biphasic
and three monophasic adeno-myoepithelial tumours
yielded similar results. We found Ck5-positive tumour
cells, glandular (Ck8/18+) and myoepithelial cells
(SMA+), as well as cells co-expressing Ck5 and one of the
lineage differentiation markers (either Ck5+, Ck8/18+ or
Ck5+, SMA+) in all of these lesions (Fig 1, G, H).
Immmunophenotype
All tumours tested for SMA expressed this antigen. With
the exception of one case, all malignant adenomyoepithe-
lial tumours showed reactivity with antibodies directed
against vimentin. The high molecular weight cytokeratins
Ck5 and Ck14 and SMA were variably expressed in all the
tumours of this series. Furthermore, all the tumours tested
were positive for p63 and, with the exception of one
malignant neoplasm, all the lesions were at least focally
positive for Ck8/18. Reactivity with the Ck19-specific
antibody was noted in 5 of 7 (71 %) benign, in none of 3
borderline and in 8 of 12 malignant tumours. With the
exception of a single case, all tumours showed at least
focal reactivity with the antibody KL-1 directed against a
broad spectrum of cytokeratins. 78 % of all the tumours
tested displayed at least a weak reactivity with an antibody
specific for CD117 (c-Kit).
Comparative genomic hybridisation
In the group of benign adenomyoepithelial lesions, 5 of 7
tumours showed alterations comprising 13 gains and 5
losses of chromosomal regions (mean: 2.6). A total of 9
gains and 10 losses were found in 5 of the borderline
Table 2: Antibodies and immunohistological staining procedures
Antigen Antibody Source Dilution Detection Pretreatment
Vimentin mAb V9 DAKO, Glostrup, Denmark 1:1000 LSAB/ HRP Steamer
Ki-67 nuclear antigen mAb MIB-1 DAKO, Glostrup, Denmark 1:100 LSAB/AP Steamer
broad spectrum Cks mAb KL-1 Immunotech, Marseille, France 1:50 LSAB/ HRP Steamer
Ck5/6 mAb D5/16B4 Zymed, San Francisco, USA 1:50 LSAB/ AP Steamer
Ck14 mAb Ll002 dianova GmbH, Hamburg, Germany 1:50 LSAB/ AP Steamer
Ck8/18 mAb 5D3 dianova GmbH, Hamburg, Germany 1:40 LSAB/ AP Steamer
Ck19 mAb RCK108 DAKO, Glostrup, Denmark 1:80 LSAB/ AP Steamer
P63 mAb 4A4 DAKO, Glostrup, Denmark 1:100 LSAB/ AP Steamer
Sm-α-actin (SMA) mAb 1A4 DAKO, Glostrup, Denmark 1:3000 LSAB/ AP Steamer
S-100 protein Rabbit, polyclonal DAKO, Glostrup, Denmark 1:1000 LSAB/ HRP -
Estrogen receptor mAb 6F11 Novocastra, Newcastle upon Tyne, UK 1:200 LSAB/ AP Steamer
Progesterone receptor mAb 16 Novocastra, Newcastle upon Tyne, UK 1:1000 LSAB/ AP Steamer
c-Kit Rabbit, polyclonal DAKO, Glostrup, Denmark 1:100 LSAB/ AP Steamer
mAb, mouse monoclonal antibodyBMC Cancer 2005, 5:92 http://www.biomedcentral.com/1471-2407/5/92
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Conventional histology and immunostaining of two benign adenomyoepitheliomas of the breast (A,C,E,G: biphasic; B,D,F:  monophasic) Figure 1
Conventional histology and immunostaining of two benign adenomyoepitheliomas of the breast (A,C,E,G: biphasic; B,D,F: 
monophasic). A shows a prominent tubular component, whereas in B a spindle-cell architecture predominates (A, H&E, mag-
nification ×20, D, H&E, magnification ×20). C and D display distribution patterns of basal cytokeratin expression that are tan-
tamount to the proportion of tumour cells (immunostaining for Ck5/6, magnification ×20) E and F show expression of sm α-
actin (immunostaining for SMA, magnification ×20) with a distribution similar to normal breast tissue in biphasic benign adeno-
myoepithelioma. G shows double immunofluorescence staining (Ck5/6 green, Ck8/18 red, 40×) with prominent abluminal 
swarming of Ck5/6-positive cells. The proliferating glandular epithelium consists of differentiated (red signal) and less differenti-
ated (hybrid signal) glandular cells. H shows double immunofluorescence staining (Ck5 red, SMA green, 63×) of a monophasic, 
malignant myoepithelial tumour with many cells coexpressing SMA and high molecular weigh Ck5. Note some less differenti-
ated cells that express mainly Ck5 and some better differentiated cells with a predominance of SMA expression (green signal).BMC Cancer 2005, 5:92 http://www.biomedcentral.com/1471-2407/5/92
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Conventional histology and immunostaining of two malignant adenomyoepitheliomas of the breast Figure 2
Conventional histology and immunostaining of two malignant adenomyoepitheliomas of the breast. A, C and E shows a bipha-
sic malignant adenomyoepithelial tumour with distinct tubular formations, whereas B, D and F show a monophasic adenom-
yoepithelial carcinoma with diffuse infiltration of adipose tissue.(H&E, magnification ×20 C and D display distribution patterns 
of basal cytokeratin expression that are tantamount to the proportion of tumour cells (immunostaining for Ck5/6, magnifica-
tion ×20). E and F show expression of SMA in a more irregular distribution compared to normal breast tissue in the malignant 
biphasic lesion and a rather diffuse pattern in monophasic lesions. A prominent mitotic figure is marked in F (arrow) (magnifica-
tion ×20).BMC Cancer 2005, 5:92 http://www.biomedcentral.com/1471-2407/5/92
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tumours, while 3 tumours did not show any alterations
(mean: 3.8). In 14 samples of malignant adenomyoepi-
thelial tumours, a total of 94 DNA copy number changes
were seen (mean: 6.7), while four malignant adenom-
yoepithelial tumours did not display any detectable
changes (Fig. 3). With a total of 12, the changes on
chromosome 8 were most frequent. Losses of 17p were
detected in 6 malignant, 2 borderline and in 1 benign
lesion. Less frequent alterations comprised gains of 13q (5
cases) and of the short arm of chromosomes 6 and 12,
each observed in 4 cases.
Cases no. 8 and 24 were specimens obtained from a lesion
diagnosed as benign adenomyoepithelial tumour, which
nevertheless recurred two years later as a malignant
tumour.
On CGH, the only alteration shared by both tumours was
a gain of the long arm of chromosome 8, with amplifica-
tion on this arm of chromosome 8 in the malignant
recurrence.
Summary of CGH profiles of 8 benign adenomyoepitheliomas (light blue), 5 adenomyoepitheliomas of borderline type (dark  blue) and 14 adenomyoepithelial carcinomas (violet) Figure 3
Summary of CGH profiles of 8 benign adenomyoepitheliomas (light blue), 5 adenomyoepitheliomas of borderline type (dark 
blue) and 14 adenomyoepithelial carcinomas (violet). A total of 131 gains and losses are distributed over 22 chromosomes with 
a preference of chromosomes 8, 17p and 13q.BMC Cancer 2005, 5:92 http://www.biomedcentral.com/1471-2407/5/92
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We observed a stepwise, although statistically insignifi-
cant increase in the number of cytogenetic alterations per
case. Their numbers were lowest for benign tumours, but
steadily progressed in borderline and malignant adenom-
yoepithelial tumours. An elevated growth fraction corre-
lated with an increase in the number of cytogenetic
alterations (p = 0.07).
Discussion
Tumours with an adenomyoepithelial differentiation
span a broad and morphologically diverse spectrum of
neoplasms ranging from patterns with biphasic glandu-
lar/myoepithelial architecture to monophasic pure spin-
dle-cell variants. The biology of these rare tumours is
poorly understood and their complex nature often gives
rise to diagnostic uncertainty, especially when it comes to
accurately assessing the prognosis of a given case. The
hallmark of these tumours are SMA-positive neoplastic
cells co-expressing cytokeratins in variable amounts. Fur-
thermore, all of these tumours share a high proportion of
cells that are reactive for basal-type Ck5/6 and Ck14 and
p63 and most, even the monophasic ones, also contain
tumour cells with expression of glandular type Ck8/18.
This is in glaring contrast to myoepithelial carcinomas
which are defined by a complete absence of glandular fea-
tures. Nevertheless only one (case 16) of the spindle-cell
tumours included in this series met the criteria of this cat-
egory, all other tumours showed at least a small positive
reaction with glandular-type cytokeratins. This would
indicate that pure myoepithelial carcinomas are extremely
rare. This admixture of glandular and myoepithelial com-
ponents was also described in metaplastic spindle cell car-
cinoma, "fibromatosis-like" which has to be taken into
account in differential diagnosis [9]. In view of our
present morphological and immunohistochemical data,
some of these tumours might be classified as adenom-
yoepithelial tumours.
Not unexpectedly, biphasic adenomyoepithelial lesions
displayed a Ck8/18 expression that was confined to glan-
dular structures and therefore similar to patterns present
in normal breast tissue. Lesions with a monophasic "mes-
enchymal" appearance, however, displayed a Ck8/18 and
Ck19-positive immunophenotype in spindle-cells often
arranged in a reticular pattern (Figs 1 and 2. B, D, F). In
addition, double immunofluorescence experiments
showed co-expression of basal type keratins either in com-
bination with glandular type keratins or SMA as a marker
of the myoepithelial lineage. Part of the tumour cells
solely expressed Ck5/6. Within the context of a recently
published model of differentiation [6,10,11] in normal
breast tissue this data would further point towards the
existence of Ck5-positive progenitor cells with multi-line-
age differentiation potential [12-16]. The potential impor-
tance of these presumed progenitor cells has already been
shown in mouse tumours with both myoepithelial and
glandular differentiation [17].
The assumption that adenomyoepithelial neoplasms are
progenitor cell-derived lesions would help to explain the
mixed glandular and myoepithelial architecture in the
biphasic tumours as well as the bilinear immunopheno-
type in monophasic lesions. It seems that the tumour cells
retain at least some functional remnants of their physio-
logical counterparts. These include basement membrane
formation of hemidesmosomes and laminin-binding sites
and a strong polarity [18-21]. In the context of this
hypothesis, the typical architectural element of adenom-
yoepithelial tumours, namely the predominant multilay-
ered myoepithelial component with its swarming aspect
and enclosed tubules or purely reticular pattern, can be
attributed to an immature myoepithelial phenotype and
function. Especially the latter may trigger a loss of polarity
which leads to an inappropriate sorting of the myoepithe-
lial cells.
From a clinical point of view, no clear criteria for the
assessment of patient prognosis have been defined yet.
Because these tumours are so rare, available data concern-
ing the prognosis of these tumours is scarce. In accordance
with reports in the literature [4,23], we applied criteria
commonly used for assessing malignancy of these
tumours which unfortunately were shown to be lacking in
precision. Mitotic rates of up to 16 mitoses per 10 HPF
were reported in lesions categorised as benign, whereas in
contrast tumours with less than 3 mitoses per 10 HPF
were diagnosed as malignant. Additionally, ill-defined
margins and infiltrative growth patterns are observed in
tumours of this entity, although it was never conclusively
decided whether such features are indicative of a malig-
nant outcome or a remnant of normal behaviour of
myoepithelial cells as already documented in vitro [21].
Given this information, we propose a third category of
tumours of uncertain prognosis in addition to a benign
and a malignant category. The CGH analyses of our series
of adenomyoepithelial neoplasms support this idea,
because a stepwise increase in the average number of
genetic alterations was observed. Growing numbers of
genetic alterations are also associated with an increasing
growth fraction (>10 %) However, this suggests a contin-
uum in the progression of these tumours and is hardly
helpful in the assessment of individual cases. For exam-
ple, in our series 4 of 14 lesions with features of malig-
nancy did not display any gross genetic alterations. This
lack of practical applicability was painfully obvious in the
case of an 80-year-old woman (no. 8 and 24) with an
incompletely removed lesion described as benign adeno-
myoepithelial tumour. This apparently benign tumour
recurred two years later as an overtly malignant adenom-BMC Cancer 2005, 5:92 http://www.biomedcentral.com/1471-2407/5/92
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yoepithelioma. The initial tumour showed gains of
genetic material in three distinct loci including 8q,
whereas the malignant recurrence showed a further ampli-
fication on the long arm of chromosome 8 in addition to
a loss of genetic material on the long arm of chromo-
somes 11 and 12. This suggests a clonal progression of
changes already present in the initial lesion. Yet, similar to
myoepithelial tumours of the salivary glands [24], a
specific alteration pattern could not be defined for their
counterparts of the breast, a result which is nevertheless in
line with most published work in the field.
Conclusion
Our data suggests the use of a two-tiered terminology
according to which adenomyoepithelial tumours are
classified as biphasic and monophasic in terms of their
deviation from the normal architecture of the myoepithe-
lial-epithelial formation. Furthermore, our data revealed
hints for Ck5/6-positive cells as a key component in the
histiogenesis of these neoplasms. Nevertheless, any prog-
nostic assessment has to be made on morphological
grounds with special attention to proliferative activity.
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